Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib versus placebo as adjuvant therapy for EGFR-mutant stage II-IIIB non-small cell lung cancer
CTR20202460Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib, Placebo-COD Research Private Ltd in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started May 2021; status: active.
02
Drugs
almonertinibPlacebo-COD Research Private Ltd
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202460.